Covid 19 Clinical Trials

This study is aimed to investigate the effect of Famotidine in the symptomatic recovery of the different degrees of COVID-19 patients. COVID19 is a worldwide pandemic. Hence SARS-CoV-2 is a novel virus; there is no specific medication against it. Like other countries of the world, Besides antiviral drugs, immunosuppressive agents, and symptomatic therapy like H2 receptor blocker FAMOTIDINE came to limelight due to its role in reducing the symptoms of COVID-19 patients. The study will include COVID-19 participants to confirm by RT PCR or an HRCT chest. Detail history of each participant with comorbidity will be taken and will be examined carefully. Both the hospitalized and OPD patients will be enrolled in this study. Seriously ill patients who require ventilation will not be included in this study. The outcome of the Famotidine treatment will be evaluated and compared with a control group.

NCT04504240 Covid19 Drug: Famotidine 20 MG

Primary Outcomes

Description: The number of participants with "Symptomatic improvement" determined by the change of individual presenting symptoms of the COVID-19 disease. Major symptoms, fever, cough, respiratory distress, chest tightness, sore throat, and myalgia will be rerecorded daily. This will be done by the investigators in the case of the hospitalized patients and the patient itself by a daily self assessment cart in the case of OPD patients.

Measure: Symptomatic improvement

Time: Following randomization 10 days.

Description: The number of participants with "Clinical status (Stable or Deteriorate clinical state)" determined by the chart or the judgment of the investigators. This will be defined as OPD patients require hospitalization, Hospitalized patients require High Dependency Unit (HDU), and an HDU patient requiring Ventilator or Intensive care support.

Measure: "Clinical status (Stable or Deteriorate clinical state)"

Time: Following randomization 15 days.

Secondary Outcomes

Description: The number of participants with "adverse effects" determined by the existence of the pharmacological side effects of the particular drug (Famotidine) during treatment. The adverse effect will define as the symptoms expressed by the participants following the starting of the treatment other than the disease symptoms, those are within the proven/enlisted pharmacological side effects of the particular drug therapy. Adverse effects will be evaluated by the investigators during follow-ups or communication on phone or during the final collection of the recovery chart.

Measure: Adverse effects

Time: Following randomization 15 days.

CovidResearchTrials by Shray Alag

Covid 19 Research using Clinical Trials (Home Page)

Famotidine 20 MGWiki

Developed by Shray Alag

Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation

Correlated Drug Terms (3)

Correlated MeSH Terms (3)

Correlated HPO Terms (0)

Clinical Trials

1 Role of Famotidine in the Symptomatic Improvement of Moderate to Severe COVID-19 Patients

NCT04504240 Covid19 Drug: Famotidine 20 MG

Primary Outcomes

Secondary Outcomes

No related HPO nodes (Using clinical trials)